RVTY vs TECH vs TWST Stock Comparison

Revvity, Bio-Techne and Twist Bioscience Prices as of Oct 29, 2026 Peers: Industry group
1 more company in this comparison (TXG) Create a free account to keep reading and compare up to 10 companies.
RVTY Revvity, Inc.
$165.78 +8.6% 1M +74.0% 1Y
Market cap
$18.50B
P/E
77.9x
Revenue (TTM)
$2.91B
Div. yield
0.17%
Life Sciences Tools Healthcare
3 wins
TECH BIO-TECHNE Corp
$72.71 +0.5% 1M +17.2% 1Y
Market cap
$11.35B
P/E
62.4x
Revenue (TTM)
$1.22B
Div. yield
0.44%
Life Sciences Tools Healthcare
6 wins
TWST Twist Bioscience Corp
$173.45 -6.8% 1M +438.5% 1Y
Market cap
$10.87B
P/E
–
Revenue (TTM)
$431.80M
Div. yield
–
Life Sciences Tools Healthcare
3 wins

Head to Head

12 decided of 12

Bio-Techne leads on 6 of the 12 questions below (Bio-Techne 6, Revvity 3, Twist Bioscience 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRVTYTECHTWSTLeader
Larger companyMarket capitalisation $18.50B $11.35B $10.87B RVTY
Cheaper on earningsLower P/E, profitable companies only 77.9x 62.4x -79.1x TECH
Cheaper on forward earningsLower price / next fiscal year consensus EPS 32.5x 33.7x — RVTY
Faster revenue growthRevenue growth, trailing twelve months +4.1% -0.4% +19.2% TWST
More profitableNet margin, trailing twelve months 8.2% 15.0% -31.7% TECH
Better return on capitalReturn on invested capital 3.1% 8.3% -31.1% TECH
Less leveragedLower net debt / EBITDA 2.8x -0.2x 1.3x TECH
Higher dividend yieldTrailing dividend yield 0.17% 0.44% — TECH
Better 1-year returnPrice return, last 12 months +74.0% +17.2% +438.5% TWST
Better 5-year returnAnnualised price return, 5 years -1.3%/yr -11.1%/yr +7.9%/yr TWST
Less volatileAnnualised volatility, 1 year 39.8% 43.4% 79.0% RVTY
Higher overall scoreMean of the five percentile scores vs peers 58/100 66/100 51/100 TECH

Percentile Scorecard

RVTYTECHTWST

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRVTYTECHTWST
Valuation 69 #72 of 227 59 #93 of 227 30 #159 of 227
Growth 28 #157 of 218 40 #131 of 218 56 #96 of 218
Profitability 81 #40 of 202 94 #13 of 202 42 #118 of 202
Financial Health 47 #124 of 233 87 #32 of 233 73 #63 of 233
Shareholder Returns 66 #45 of 130 50 #65 of 130 51 #64 of 130
Overall 58 66 51
  • RVTY ranked among 247 companies in Medical Devices and Diagnostics
  • TECH ranked among 247 companies in Medical Devices and Diagnostics
  • TWST ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRVTYTECHTWSTSPY
1 month +8.6%+0.5%-6.8% +0.7%
3 months +46.0%+0.9%+89.9% +3.7%
6 months +91.4%+31.4%+196.7% +7.1%
Year to date +71.3%+23.6%+446.8% +12.8%
1 year +74.0%+17.2%+438.5% +11.9%
3 years +102.0%+28.4%+1,050.2% +85.2%
3 years, per year +26.4%+8.7%+125.9% +22.8%
5 years -6.3%-44.5%+46.0% +67.6%
5 years, per year -1.3%-11.1%+7.9% +10.9%
10 years +226.3%+187.9%— +262.0%
10 years, per year +12.6%+11.2%— +13.7%

Risk

MeasureRVTYTECHTWSTSPY
Volatility, 1Y 39.8%43.4%79.0% 12.7%
Downside volatility, 1Y 36.0%43.6%69.8% 12.6%
Beta vs S&P 500, 1Y 1.230.772.71 1.00
Return / volatility, 1Y 1.860.405.55 0.94
Max drawdown, 5Y -59.2%-67.0%-91.5% -25.4%
From 52-week high 0.0%0.0%-15.4% -1.2%
52-week high $165.78$72.71$205.00 $779.14
52-week low $82.26$43.30$25.45 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRVTYTECHTWST
P/E now vs peer median 77.9xmedian 28.7x 62.4xmedian 28.7x -79.1xmedian 28.7x
P/S now vs peer median 6.4xmedian 3.0x 9.3xmedian 3.0x 25.2xmedian 3.0x
EV/EBITDA now vs peer median 26.7xmedian 17.8x 32.3xmedian 17.8x -89.6xmedian 17.8x
P/FCF now vs peer median 32.5xmedian 26.4x 43.1xmedian 26.4x -110.8xmedian 26.4x
P/B now vs peer median 2.6xmedian 2.4x 5.4xmedian 2.4x 24.4xmedian 2.4x
PEG now vs peer median -2.50median 0.99 -4.78median 0.99 -5.01median 0.99

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRVTYTECHTWST
Revenue $2.91B $1.22B $431.80M
Gross profit $1.60B $799.07M $224.39M
Operating income $358.85M $251.89M -$144.98M
Net income $237.55M $181.86M -$136.80M
Free cash flow $568.85M $263.22M -$98.12M
R&D $215.83M $94.77M $71.86M
EPS (diluted) $2.13 $1.16 $-2.19
Cash & equivalents $1.02B $264.71M $117.44M
Total debt $3.21B $200.00M $15.00M
Shares (diluted) 111.63M 157.01M 62.40M
Enterprise value $14.76B $10.56B $10.10B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRVTYTECHTWST
P/E 77.9x 62.4x -79.1x
P/FCF 32.5x 43.1x -110.8x
P/Operating cash flow 29.0x 38.9x -204.8x
P/S 6.4x 9.3x 25.2x
P/B 2.6x 5.4x 24.4x
P/Tangible book 3.7x 6.3x 25.1x
EV/EBITDA 26.7x 32.3x -89.6x
EV/EBIT 57.6x 44.8x -73.9x
EV/Revenue 7.1x 9.3x 24.8x
EV/FCF 36.4x 42.9x -109.2x
EV/Operating cash flow 32.4x 38.6x -202.0x
PEG (3Y EPS CAGR) -2.50 -4.78 -5.01

Growth

14 metrics
MetricRVTYTECHTWST
Revenue growth (1Y) 4.1% -0.4% 19.2%
Revenue CAGR (3Y) 0.9% 2.2% 22.4%
Gross profit growth (1Y) 2.3% 1.1% 25.8%
Gross profit CAGR (3Y) -0.4% 1.3% 35.1%
Operating income growth (1Y) -5.5% 146.3% -1.8%
Operating income CAGR (3Y) -3.7% -5.5% 13.5%
Net income growth (1Y) -16.7% 147.8% -60.6%
Net income CAGR (3Y) -33.8% -14.0% 13.2%
EPS growth (1Y) -12.3% 152.0% -57.5%
EPS CAGR (3Y) -31.2% -13.1% 15.8%
Operating cash flow growth (1Y) 6.2% 1.6% -3.8%
Operating cash flow CAGR (3Y) 86.9% 4.7% 24.4%
Free cash flow growth (1Y) 9.5% 2.6% -42.8%
Free cash flow CAGR (3Y) 64.8% 6.8% 15.9%

Profitability

14 metrics
MetricRVTYTECHTWST
Gross margin 55.0% 65.8% 52.0%
EBITDA margin 26.6% 28.7% -27.7%
Operating margin 12.3% 20.7% -33.6%
Pretax margin 9.0% 19.8% -31.5%
Net margin 8.2% 15.0% -31.7%
FCF margin 19.5% 21.7% -22.7%
Operating cash flow margin 21.9% 24.0% -12.3%
Return on equity 3.3% 8.7% -30.4%
Return on assets 2.0% 7.1% -20.3%
Return on invested capital 3.1% 8.3% -31.1%
Return on capital employed 3.3% 10.5% -26.2%
Asset turnover 0.2x 0.5x 0.6x
Cash conversion (OCF / net income) 2.7x 1.6x 0.4x
Stock comp / revenue 0.8% 0.5% 15.4%

Financial Health

11 metrics
MetricRVTYTECHTWST
Debt / assets 26.6% 7.7% 2.2%
Debt / equity 0.4x 0.1x 0.0x
Net debt / EBITDA 2.8x -0.2x 1.3x
Debt / FCF 5.6x 0.8x -0.2x
Liabilities / assets 40.0% 18.5% 33.7%
Equity / assets 60.0% 81.5% 66.3%
Interest coverage 3.7x 26.2x –
Current ratio 1.8x 4.5x 2.7x
Quick ratio 1.4x 2.9x 1.9x
Cash ratio 0.8x 1.6x 1.4x
Altman Z-score 3.46 15.91 26.09

Shareholder Returns

7 metrics
MetricRVTYTECHTWST
Dividend yield 0.2% 0.4% –
Net buyback yield 2.5% -0.3% -0.1%
Shareholder yield 2.7% 0.1% -0.1%
Payout ratio (earnings) 13.4% 27.4% –
Payout ratio (FCF) 5.6% 19.0% –
Dividend growth (1Y) -6.3% -0.9% –
Dividend CAGR (3Y) -6.1% -0.2% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRVTYTECHTWST
Forward P/E 32.5xFY2026 33.7xFY2027 –
EPS, next fiscal year $5.10FY2026 $2.16FY2027 $-2.02FY2026
EPS growth, next FY +0.8%FY2026 +11.9%FY2027 –
EPS growth, the year after +11.0% +5.1% –
Revenue, next fiscal year $2.98BFY2026 $1.19BFY2027 $469.33MFY2026
Revenue growth, next FY +4.0%FY2026 -2.1%FY2027 +24.6%FY2026
Revenue growth, the year after -2.0% +13.5% +21.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRVTYTECHTWST
Held by institutions 100.0% 100.0% 100.0%
Institutions holding 546 598 336
Change in shares held, QoQ -1.3% -0.6% -0.8%
Institutions buying 302 293 189
Institutions selling 161 241 102
Buyers to sellers 1.88 1.22 1.85

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RVTYTECHTWST
RVTY 1.00 0.45 0.53
TECH 0.45 1.00 0.32
TWST 0.53 0.32 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RVTY, TECH and TWST?

Revvity (RVTY) is the largest by market capitalisation: Revvity (RVTY) $18.50B, Bio-Techne (TECH) $11.35B, Twist Bioscience (TWST) $10.87B.

Which stock is cheaper, RVTY, TECH and TWST?

Bio-Techne (TECH) trades on the lowest price-to-earnings ratio (Revvity (RVTY) 77.9x, Bio-Techne (TECH) 62.4x, Twist Bioscience (TWST) -79.1x). On next year's consensus earnings, Revvity (RVTY) is cheapest (Revvity (RVTY) 32.5x, Bio-Techne (TECH) 33.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Twist Bioscience (TWST) grew revenue fastest over the trailing twelve months: Revvity (RVTY) +4.1%, Bio-Techne (TECH) -0.4%, Twist Bioscience (TWST) +19.2%.

Which company is more profitable?

Bio-Techne (TECH) has the highest net margin (Revvity (RVTY) 8.2%, Bio-Techne (TECH) 15.0%, Twist Bioscience (TWST) -31.7%). On return on invested capital, Bio-Techne (TECH) leads (Revvity (RVTY) 3.1%, Bio-Techne (TECH) 8.3%, Twist Bioscience (TWST) -31.1%).

Which stock has performed better?

Over the past year Twist Bioscience (TWST) returned the most: Revvity (RVTY) +74.0%, Bio-Techne (TECH) +17.2%, Twist Bioscience (TWST) +438.5%. Over five years, Twist Bioscience (TWST) compounded fastest (Revvity (RVTY) -1.3%/yr, Bio-Techne (TECH) -11.1%/yr, Twist Bioscience (TWST) +7.9%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bio-Techne (TECH) has the highest dividend yield: Revvity (RVTY) 0.17%, Bio-Techne (TECH) 0.44%. Twist Bioscience (TWST) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Revvity (RVTY) has been the steadiest (Revvity (RVTY) 39.8%, Bio-Techne (TECH) 43.4%, Twist Bioscience (TWST) 79.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RVTY, TECH and TWST?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Bio-Techne (TECH) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.